miR‑888 functions as an oncogene and predicts poor prognosis in colorectal cancer

Gao,Su‑Jun; Chen,Lei; Lu,Wei; Zhang,Li; Wang,Lu; Zhu,Hai‑Hang

doi:10.3892/ol.2018.8461

miR‑888 functions as an oncogene and predicts poor prognosis in colorectal cancer

Authors:
- Su‑Jun Gao
- Lei Chen
- Wei Lu
- Li Zhang
- Lu Wang
- Hai‑Hang Zhu
View Affiliations

Affiliations: Digestive Department of Subei People's Hospital, Clinical College of Yangzhou University, Yangzhou 225001, P.R. China
Published online on: April 11, 2018 https://doi.org/10.3892/ol.2018.8461
Pages: 9101-9109

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are important regulators of tumor formation, progression and metastasis. The present study characterized a novel miRNA (miR)‑888, as a potent oncomiR in human colorectal cancer (CRC). The clinicopathological investigation on 126 cases of CRC patients demonstrated that the expression level of miR‑888 was significantly upregulated in tumors compared with adjacent healthy tissue, and was associated with tumor stage and histological differentiation. A Kaplan‑Meier analysis and log‑rank test demonstrated that CRC patients with increased miR‑888 expression exhibited a decreased overall survival (OS) and disease‑free survival (DFS) compared with patients with low miR‑888 expression. Further univariate and multivariate analyses identified miR‑888 as an independent prognostic factor for poor survival outcome in CRC patients. To determine the biological role of miR‑888 in human CRC, in vitro Cell Counting kit‑8, wound healing and transwell assays were performed and demonstrated that miR‑888 contributed greatly to CRC cell proliferation, invasion and metastasis. Furthermore, potential targets of miR‑888 were investigated using a luciferase reporter assay, followed by polymerase chain reaction and western blot analysis. The findings revealed that miR‑888 directly bound to the 3'‑untranslated region of mothers against decapentaplegic‑4 and thus inhibited its expression and promoted the tumor growth factor‑1‑induced cancer metastasis signaling. The results of the present study identified miR‑888 as an oncogenic miRNA in CRC and provide a foundation for promising research in the future regarding this predictive and prognostic biomarker.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Verma AM, Patel M, Aslam MI, Jameson J, Pringle JH, Wurm P and Singh B: Circulating plasma microRNAs as a screening method for detection of colorectal adenomas. Lancet. 385 Suppl 1:S1002015. View Article : Google Scholar : PubMed/NCBI
3	Lan YT, Yang SH, Chang SC, Liang WY, Li AF, Wang HS, Jiang JK, Chen WS, Lin TC and Lin JK: Analysis of the seventh edition of American Joint Committee on colon cancer staging. Int J Colorectal Dis. 27:657–663. 2012. View Article : Google Scholar : PubMed/NCBI
4	Van Cutsem E, Cervantes A, Nordlinger B and Arnold D: ESMO Guidelines Working Group: Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25 Suppl 3:iii1–9. 2014. View Article : Google Scholar : PubMed/NCBI
5	De Rosa M, Rega D, Costabile V, Duraturo F, Niglio A, Izzo P, Pace U and Delrio P: The biological complexity of colorectal cancer: Insights into biomarkers for early detection and personalized care. Therap Adv Gastroenterol. 9:861–886. 2016. View Article : Google Scholar : PubMed/NCBI
6	Aghagolzadeh P and Radpour R: New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol. 22:5678–5693. 2016. View Article : Google Scholar : PubMed/NCBI
7	Guan X: Cancer metastases: Challenges and opportunities. Acta Pharm Sin B. 5:402–418. 2015. View Article : Google Scholar : PubMed/NCBI
8	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
9	Svoronos AA, Engelman DM and Slack FJ: OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res. 76:3666–3670. 2016. View Article : Google Scholar : PubMed/NCBI
10	Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G and Calin GA: microRNA therapeutics in cancer-an emerging concept. EBioMedicine. 12:34–42. 2016. View Article : Google Scholar : PubMed/NCBI
11	Behbahani GD, Ghahhari NM, Javidi MA, Molan AF, Feizi N and Babashah S: MicroRNA-mediated post-transcriptional regulation of epithelial to mesenchymal transition in cancer. Pathol Oncol Res. 23:1–12. 2017. View Article : Google Scholar : PubMed/NCBI
12	Mohammadi A, Mansoori B and Baradaran B: The role of microRNAs in colorectal cancer. Biomed Pharmacother. 84:705–713. 2016. View Article : Google Scholar : PubMed/NCBI
13	Hovey AM, Devor EJ, Breheny PJ, Mott SL, Dai D, Thiel KW and Leslie KK: miR-888: A Novel cancer-testis antigen that targets the progesterone receptor in endometrial cancer. Transl Oncol. 8:85–96. 2015. View Article : Google Scholar : PubMed/NCBI
14	Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, Benzine T, Madric K, Semmes OJ, Drake R and Esquela-Kerscher A: miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle. 13:227–239. 2014. View Article : Google Scholar : PubMed/NCBI
15	Huang S and Chen L: MiR-888 regulates side population properties and cancer metastasis in breast cancer cells. Biochem Biophys Res Commun. 450:1234–1240. 2014. View Article : Google Scholar : PubMed/NCBI
16	Bader AG: miR-888: Hit it when you see it! Cell Cycle. 13:3512014. View Article : Google Scholar : PubMed/NCBI
17	Huang S, Cai M, Zheng Y, Zhou L, Wang Q and Chen L: miR-888 in MCF-7 side population sphere cells directly targets E-cadherin. J Genet Genomics. 41:35–42. 2014. View Article : Google Scholar : PubMed/NCBI
18	Chen Z, Liu S, Tian L, Wu M, Ai F, Tang W, Zhao L, Ding J, Zhang L and Tang A: miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. Oncotarget. 6:38139–38150. 2015. View Article : Google Scholar : PubMed/NCBI
19	Cao ZG, Li JJ, Yao L, Huang YN, Liu YR, Hu X, Song CG and Shao ZM: High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer. Oncotarget. 7:64900–64909. 2016. View Article : Google Scholar : PubMed/NCBI
20	Shen J, Song G, An M, Li X, Wu N, Ruan K, Hu J and Hu R: The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy. Biomaterials. 35:316–326. 2014. View Article : Google Scholar : PubMed/NCBI
21	Duff EK and Clarke AR: Smad4 (DPC4)-a potent tumour suppressor? Br J Cancer. 78:1615–1619. 1998. View Article : Google Scholar : PubMed/NCBI
22	Demagny H and De Robertis EM: Smad4/DPC4: A barrier against tumor progression driven by RTK/Ras/Erk and Wnt/GSK3 signaling. Mol Cell Oncol. 3:e9891332016. View Article : Google Scholar : PubMed/NCBI
23	Weng M, Wu D, Yang C, Peng H, Wang G, Wang T and Li X: Noncoding RNAs in the development, diagnosis, and prognosis of colorectal cancer. Transl Res. 181:108–120. 2017. View Article : Google Scholar : PubMed/NCBI
24	Sinicrope FA, Okamoto K, Kasi PM and Kawakami H: Molecular biomarkers in the personalized treatment of colorectal cancer. Clin Gastroenterol Hepatol. 14:651–658. 2016. View Article : Google Scholar : PubMed/NCBI
25	Marrero JA and Lok AS: Newer markers for hepatocellular carcinoma. Gastroenterology. 127 5 Suppl 1:S113–S119. 2004. View Article : Google Scholar : PubMed/NCBI
26	Heneghan HM, Miller N and Kerin MJ: MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol. 10:543–550. 2010. View Article : Google Scholar : PubMed/NCBI
27	Wang J, Du Y, Liu X, Cho WC and Yang Y: MicroRNAs as regulator of signaling networks in metastatic colon cancer. Biomed Res Int. 2015:8236202015.PubMed/NCBI
28	Zhang Q, Yu N and Lee C: Vicious cycle of TGF-β signaling in tumor progression and metastasis. Am J Clin Exp Urol. 2:149–155. 2014.PubMed/NCBI
29	Drabsch Y and ten Dijke P: TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 31:553–568. 2012. View Article : Google Scholar : PubMed/NCBI
30	Matsuzaki K, Seki T and Okazaki K: TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases. J Gastroenterol. 49:971–981. 2014. View Article : Google Scholar : PubMed/NCBI
31	Inamoto S, Itatani Y, Yamamoto T, Minamiguchi S, Hirai H, Iwamoto M, Hasegawa S, Taketo MM, Sakai Y and Kawada K: Loss of SMAD4 promotes colorectal cancer progression by accumulation of myeloid-derived suppressor cells through the CCL15-CCR1 Chemokine Axis. Clin Cancer Res. 22:492–501. 2016. View Article : Google Scholar : PubMed/NCBI
32	Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, Day F, Li S, Tsui C, Lipton L, et al: SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 73:725–735. 2013. View Article : Google Scholar : PubMed/NCBI
33	Singh S, Narang AS and Mahato RI: Subcellular fate and off-target effects of siRNA, shRNA and miRNA. Pharm Res. 28:2996–3015. 2011. View Article : Google Scholar : PubMed/NCBI
34	Jackson AL and Linsley PS: Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 9:57–67. 2010. View Article : Google Scholar : PubMed/NCBI
35	Serrano-Gomez SJ, Maziveyi M and Alahari SK: Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 15:182016. View Article : Google Scholar : PubMed/NCBI
36	Steinestel K, Eder S, Schrader AJ and Steinestel J: Clinical significance of epithelial-mesenchymal transition. Clin Transl Med. 3:172014. View Article : Google Scholar : PubMed/NCBI
37	Saitoh M: Epithelial-mesenchymal transition is regulated at post-transcriptional levels by transforming growth factor-β signaling during tumor progression. Cancer Sci. 106:481–488. 2015. View Article : Google Scholar : PubMed/NCBI
38	Katsuno Y, Lamouille S and Derynck R: TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar : PubMed/NCBI
39	Shah PP and Kakar SS: Pituitary tumor transforming gene induces epithelial to mesenchymal transition by regulation of Twist, Snail, Slug, and E-cadherin. Cancer Lett. 311:66–76. 2011. View Article : Google Scholar : PubMed/NCBI